6-K
Oncolytics Biotech Inc (ONCY)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2025
Commission File Number 001-38512
Oncolytics Biotech Inc.
(Translation of registrant's name into English)
Suite 804, 322 11th Avenue SW
Calgary, Alberta, Canada T2R 0C5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| Form 20-F þ | Form 40-F o |
|---|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's “home country”), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
| EXHIBIT<br>NUMBER | DESCRIPTION |
|---|---|
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Oncolytics Biotech Inc.<br><br>(Registrant) | ||
|---|---|---|
| By: | /s/ Kirk Look | |
| Date: August 11, 2025 | Kirk Look<br>Chief Financial Officer |
Document
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO, CA, August 11, 2025 -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) (“Oncolytics” or the “Corporation” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
| Director | For | % | Withheld | % |
|---|---|---|---|---|
| Patricia Andrews | 10,498,328 | 88.83% | 1,320,714 | 11.17% |
| Deborah M. Brown | 10,115,110 | 85.58% | 1,703,932 | 14.42% |
| Jared Kelly | 10,830,605 | 91.64% | 988,437 | 8.36% |
| Angela Holtham | 10,175,887 | 86.10% | 1,643,155 | 13.90% |
| James T. Parsons | 10,172,958 | 86.07% | 1,646,084 | 13.93% |
| Wayne Pisano | 10,148,894 | 85.87% | 1,670,148 | 14.13% |
| Jonathan Rigby | 9,508,770 | 80.45% | 2,310,272 | 19.55% |
| Bernd R. Seizinger | 10,269,441 | 86.89% | 1,549,601 | 13.11% |
In addition to the election of all nominees listed as directors in the management information circular, dated June 18, 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.
For more details on the matters covered at the annual meeting, please refer to the Corporation’s management information circular available on SEDAR at https://www.sedarplus.ca/home/. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications